Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib, Cediranib, Capivasertib, and Durvalumab in Recurrent or Persistent Endometrial Cancer
NCT03660826Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of olaparib, cediranib, capivasertib, durvalumab in endometrial cancer (EC), sponsored by National Cancer Institute. Started Sep 2018; status: active, not recruiting.
02
Drugs
olaparibcediranibcapivasertibdurvalumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03660826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660826.